Citations (91)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Runwei Jiao, Fanxing Xu, Xiaofang Huang, Haonan Li, Weiwei Liu, Hao Cao, Linghe Zang, Zhanlin Li, Huiming Hua & Dahong Li. (2020) Antiproliferative chromone derivatives induce K562 cell death through endogenous and exogenous pathways. Journal of Enzyme Inhibition and Medicinal Chemistry 35:1, pages 759-772.
Read now
Read now
Józefa Węsierska-Gądek & Matthias P Kramer. (2011) The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications. Expert Opinion on Investigational Drugs 20:12, pages 1611-1628.
Read now
Read now
Mayer Fishman & Scott Antonia. (2003) Novel therapies for renal cell carcinoma – an update. Expert Opinion on Investigational Drugs 12:4, pages 593-609.
Read now
Read now
Articles from other publishers (88)
Esra Bozgeyik & Ibrahim Bozgeyik. (2023) Unveiling the therapeutic potential of natural-based anticancer compounds inducing non-canonical cell death mechanisms. Pathology - Research and Practice 248, pages 154693.
Crossref
Crossref
Tanja Hell, Maciej Dobrzyński, Fabian Gröflin, Jakob K. Reinhardt, Lara Dürr, Olivier Pertz, Matthias Hamburger & Eliane Garo. (2022) Flavonoids from Ericameria nauseosa inhibiting PI3K/AKT pathway in human melanoma cells. Biomedicine & Pharmacotherapy 156, pages 113754.
Crossref
Crossref
Igbokwe Chikodili, Ibe Chioma, Nnorom Chinwendu & Ejiofor IfedibaluChukwu. (2022) In-silico study for African plants with possible beta-cell regeneration effect through inhibition of DYRK1A. Sciences of Phytochemistry 1:1, pages 13-28.
Crossref
Crossref
Gizem Akman. 2022. Handbook of Research on Advanced Phytochemicals and Plant-Based Drug Discovery. Handbook of Research on Advanced Phytochemicals and Plant-Based Drug Discovery
246
266
.
Thapi D. Rao, Mengyao Xu, Stephanie Eng, Guangli Yang, Robin Manson, Nestor Rosales, Raj Kumar, Irva E. Veillard, Qin Zhou, Alexia Iasonos, Ouathek Ouerfelli, Hakim Djaballah, David R. Spriggs & Oladapo O. Yeku. (2022) Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents. Molecular Cancer Therapeutics 21:5, pages 775-785.
Crossref
Crossref
Junsha An, Cheng Peng, Xiaofang Xie & Fu Peng. (2022) New Advances in Targeted Therapy of HER2-Negative Breast Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Salman Khursheed, Sartaj Tabassum & Farukh Arjmand. (2022) Comprehensive biological {DNA/RNA binding profile, cleavage &cytotoxicity activity} of structurally well-characterized chromone-appended Cu(II)(L1-3)(phen) potential anticancer drug candidates. Polyhedron 214, pages 115638.
Crossref
Crossref
Vaishali M. Patil, Neeraj Masand, Saroj Verma & Vijay Masand. (2021) Chromones: Privileged scaffold in anticancer drug discovery. Chemical Biology & Drug Design 98:5, pages 943-953.
Crossref
Crossref
Xu Han, Ning Song, Abdusaid Saidahmatov, Peipei Wang, Yong Wang, Xiaobei Hu, Weijuan Kan, Wei Zhu, Lixin Gao, Mingjie Zeng, Yujie Wang, Chunpu Li, Jia Li, Hong Liu, Yubo Zhou & Jiang Wang. (2021) Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry 64:19, pages 14647-14663.
Crossref
Crossref
Rosa Wijnen, Camilla Pecoraro, Daniela Carbone, Hamid Fiuji, Amir Avan, Godefridus J. Peters, Elisa Giovannetti & Patrizia Diana. (2021) Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers 13:17, pages 4389.
Crossref
Crossref
Ashish Kumar, Neeraj Kumar & Balwan Singh. (2021) In Silico Analysis of Laccifer Lacca as a Potential Therapeutic Agent for Cervical, Breast and Lung Cancers. Journal of Drug Delivery and Therapeutics 11:3, pages 79-85.
Crossref
Crossref
Kent T.J. Chen, Gardenia G.C. Militao, Malathi Anantha, Dominik Witzigmann, Ada W.Y. Leung & Marcel B. Bally. (2021) Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. Journal of Controlled Release 333, pages 246-257.
Crossref
Crossref
Bharat Goel, Nancy Tripathi, Nivedita Bhardwaj & Shreyans K. Jain. (2020) Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. Current Topics in Medicinal Chemistry 20:17, pages 1535-1563.
Crossref
Crossref
Nihay Laham-Karam, Gaspar P. Pinto, Antti Poso & Piia Kokkonen. (2020) Transcription and Translation Inhibitors in Cancer Treatment. Frontiers in Chemistry 8.
Crossref
Crossref
Wen-Hui Zhang, Shuang Chen, Xiong-Li Liu, Ting-Ting Feng, Wu-De Yang & Ying Zhou. (2019) Design, synthesis and evaluation of structurally diverse chrysin-chromene-spirooxindole hybrids as anticancer agents. Bioorganic & Medicinal Chemistry 27:22, pages 115109.
Crossref
Crossref
Kent T. J. Chen, Roger Gilabert-Oriol, Marcel B. Bally & Ada W. Y. Leung. (2019) Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. Pharmaceutical Research 36:9.
Crossref
Crossref
Lulu Zhao, Xinyu Yuan, Jubo Wang, Yifan Feng, Fei Ji, Zhiyu Li & Jinlei Bian. (2019) A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs. Bioorganic & Medicinal Chemistry 27:5, pages 677-685.
Crossref
Crossref
Pranav Gupta, Silpa Narayanan & Dong-Hua Yang. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
125
149
.
Sunil K. Deshmukh, Manish K. Gupta & Sangram K. Lenka. 2019. Microbial Diversity in Ecosystem Sustainability and Biotechnological Applications. Microbial Diversity in Ecosystem Sustainability and Biotechnological Applications
493
532
.
Sven Marcel Stefan & Michael Wiese. (2019) Small-molecule inhibitors of multidrug resistance-associated protein 1 and related processes: A historic approach and recent advances. Medicinal Research Reviews 39:1, pages 176-264.
Crossref
Crossref
Vaishali M. Patil & Neeraj Masand. 2018.
401
430
.
Hanxiao Xu, Shengnan Yu, Qian Liu, Xun Yuan, Sridhar Mani, Richard G. Pestell & Kongming Wu. (2017) Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Yu Zhang, Liang Zhou, Yun Leng, Yun Dai, Robert Z. Orlowski & Steven Grant. (2017) Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8:35, pages 59476-59491.
Crossref
Crossref
Xiaoran Li, Jie Lu, Quancheng Kan, Xiaoli Li, Qiong Fan, Yaqing Li, Ruixia Huang, Ana Slipicevic, Hiep Phuc Dong, Lars Eide, Junbai Wang, Hongquan Zhang, Viktor Berge, Mariusz Adam Goscinski, Gunnar Kvalheim, Jahn M. Nesland & Zhenhe Suo. (2017) Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. Scientific Reports 7:1.
Crossref
Crossref
Saúl Redondo-Blanco, Javier Fernández, Ignacio Gutiérrez-del-Río, Claudio J. Villar & Felipe Lombó. (2017) New Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds. Frontiers in Pharmacology 8.
Crossref
Crossref
Kumari Varsha, Ankita Sharma, Amanpreet Kaur, Jitender Madan, Ravi S. Pandey, Upendra K. Jain & Ramesh Chandra. 2017. Nanostructures for Cancer Therapy. Nanostructures for Cancer Therapy
775
809
.
Stephen Safe & Ravi Kasiappan. (2016) Natural Products as Mechanism-based Anticancer Agents: Sp Transcription Factors as Targets. Phytotherapy Research 30:11, pages 1723-1732.
Crossref
Crossref
Silvia Stotani, Fabrizio Giordanetto & Federico Medda. (2016) DYRK1A inhibition as potential treatment for Alzheimer’s disease. Future Medicinal Chemistry 8:6, pages 681-696.
Crossref
Crossref
Jing Liu, Jin Lin, Lin-Feng Huang, Bo Huang, Yan-Mei Xu, Jing Li, Yan Wang, Jing Zhang, Wei-Ming Yang, Qing-Hua Min & Xiao-Zhong Wang. (2015) Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells. Tumor Biology 36:10, pages 8127-8136.
Crossref
Crossref
Karam Chand, Rakesh K Tiwari, Sumit Kumar, Amir Nasrolahi Shirazi, Sweta Sharma, Erik V Van der Eycken, Virinder S Parmar, Keykavous Parang & Sunil K Sharma. (2015)
Synthesis, Antiproliferative, and c-Src Kinase Inhibitory Activities of 4-Oxo-4
H
-1-benzopyran Derivatives
. Journal of Heterocyclic Chemistry 52:2, pages 562-572.
Crossref
Crossref
Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner & Erik S. Knudsen. (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery 14:2, pages 130-146.
Crossref
Crossref
Guangjie Yang, Hukui Sun, Yu Kong, Guihua Hou & Jiankui Han. (2014) Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice. Nuclear Medicine and Biology 41:10, pages 856-862.
Crossref
Crossref
Jyothi Madda, Akkaladevi Venkatesham, Bejjanki Naveen Kumar, Kommu Nagaiah, Pombala Sujitha, C. Ganesh Kumar, Tadikamalla Prabhakar Rao & Nanubolu Jagadeesh Babu. (2014) Synthesis of novel chromeno-annulated cis -fused pyrano[3,4- c ]benzopyran and naphtho pyran derivatives via domino aldol-type/hetero Diels–Alder reaction and their cytotoxicity evaluation. Bioorganic & Medicinal Chemistry Letters 24:18, pages 4428-4434.
Crossref
Crossref
Lipeng Wu, Li Li, Bo Zhou, Zhaohui Qin & Yali Dou. (2014) H2B Ubiquitylation Promotes RNA Pol II Processivity via PAF1 and pTEFb. Molecular Cell 54:6, pages 920-931.
Crossref
Crossref
P. Lokesh, S. Balasubramanya & M. Anuradha. (2013) Cost effective quantification of camptothecin and a comparative study of its content in Nothapodytes foetida and Ophiorrhiza mungos sourced from selected geographical locations. Oriental Pharmacy and Experimental Medicine 14:2, pages 87-92.
Crossref
Crossref
Michael F. Primik, Lukas K. Filak & Vladimir B. Arion. 2013. Advances in Organometallic Chemistry and Catalysis. Advances in Organometallic Chemistry and Catalysis
605
617
.
Guannan Liu, Zhen Ge, Mengdan Zhao & Yifeng Zhou. (2013) Design, Synthesis and Cytotoxic Activities of Novel Aliphatic Amino-Substituted Flavonoids. Molecules 18:11, pages 14070-14084.
Crossref
Crossref
Reine Nehmé, Hala Nehmé, Grégory Roux, Emilie Destandau, Bérengère Claude & Philippe Morin. (2013) Capillary electrophoresis as a novel technique for screening natural flavonoids as kinase inhibitors. Journal of Chromatography A 1318, pages 257-264.
Crossref
Crossref
Kumudha Balakrishnan & Varsha Gandhi. (2013) Bcl-2 antagonists: a proof of concept for CLL therapy. Investigational New Drugs 31:5, pages 1384-1394.
Crossref
Crossref
Michael F. Primik, Simone Göschl, Samuel M. Meier, Nadine Eberherr, Michael A. Jakupec, Éva A. Enyedy, Ghenadie Novitchi & Vladimir B. Arion. (2013)
Dicopper(II) and Dizinc(II) Complexes with Nonsymmetric Dinucleating Ligands Based on Indolo[3,2-
c
]quinolines: Synthesis, Structure, Cytotoxicity, and Intracellular Distribution
. Inorganic Chemistry 52:17, pages 10137-10146.
Crossref
Crossref
Wei Huang, Qiong Chen, Wen-Chao Yang & Guang-Fu Yang. (2013) Efficient synthesis and antiproliferative activity of novel thioether-substituted flavonoids. European Journal of Medicinal Chemistry 66, pages 161-170.
Crossref
Crossref
Chen Lin, Pei-Jung Lu, Chia-Ning Yang, Christopher Hulme & Arthur Y. Shaw. (2012) Structure–activity relationship study of growth inhibitory 2-styrylchromones against carcinoma cells. Medicinal Chemistry Research 22:5, pages 2385-2394.
Crossref
Crossref
Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernan Carol, Richard Lock, Doris Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine Billups & Malcolm A. Smith. (2012) Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatric Blood & Cancer 59:7, pages 1266-1274.
Crossref
Crossref
Tsuguaki Terashima, Abedul Haque, Yuka Kajita, Akinori Takeuchi, Takashi Nakagawa & Takashi Yokochi. (2012) Flavopiridol inhibits interferon-γ-induced nitric oxide production in mouse vascular endothelial cells. Immunology Letters 148:2, pages 91-96.
Crossref
Crossref
Reza K Oqani, Hong R Kim, Yun F Diao, Chang S Park & Dong I Jin. (2011) The CDK9/Cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: A possible role in embryonic genome activation. BMC Developmental Biology 11:1.
Crossref
Crossref
Baojian Wu, Kaustubh Kulkarni, Sumit Basu, Shuxing Zhang & Ming Hu. (2011) First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics. Journal of Pharmaceutical Sciences 100:9, pages 3655-3681.
Crossref
Crossref
Patel Mohanakumara, Nambiar Sreejayan, Vaidayanathan Priti, Bheemanahally Thimmappa Ramesha, Gudasalamani Ravikanth, Kotiganahalli Narayanagowda Ganeshaiah, Ramesh Vasudeva, John Mohan, Thankayyan Retnabai Santhoshkumar, Prabhu Dutt Mishra, Viswakarma Ram & Ramanan Uma Shaanker. (2010) Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine. Fitoterapia 81:2, pages 145-148.
Crossref
Crossref
Rong Chen & William Plunkett. (2010) Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia. Best Practice & Research Clinical Haematology 23:1, pages 155-166.
Crossref
Crossref
Tilak Raj, Richa Kaur Bhatia, Ashish kapur, Madhunika Sharma, A.K. Saxena & M.P.S. Ishar. (2010) Cytotoxic activity of 3-(5-phenyl-3 H -[1,2,4]dithiazol-3-yl)chromen-4-ones and 4-oxo-4 H -chromene-3-carbothioic acid N -phenylamides. European Journal of Medicinal Chemistry 45:2, pages 790-794.
Crossref
Crossref
Alexander Levitzki. 2010. Handbook of Cell Signaling. Handbook of Cell Signaling
481
490
.
Wei Huang, Yu Ding, Yan Miao, Ming-Zhen Liu, Yan Li & Guang-Fu Yang. (2009) Synthesis and antitumor activity of novel dithiocarbamate substituted chromones. European Journal of Medicinal Chemistry 44:9, pages 3687-3696.
Crossref
Crossref
Christine M. Stellrecht & Varsha Gandhi. (2009) MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Letters 280:1, pages 1-14.
Crossref
Crossref
Anne S. Tsao. (2009) Novel therapies in metastatic head and neck squamous cell carcinoma. Community Oncology 6:7, pages 310-316.
Crossref
Crossref
Saby George, Basil S. Kasimis, Janet Cogswell, Paul Schwarzenberger, Geoffrey I. Shapiro, Panos Fidias & Ronald M. Bukowski. (2008) Phase I Study of Flavopiridol in Combination with Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer. Clinical Lung Cancer 9:3, pages 160-165.
Crossref
Crossref
Ramiro Araya-Maturana, Jorge Heredia-Moya, Oscar Donoso-Tauda, Mario Vera, Jorge Toledo Hernández, Mario Pavani, Hernán Pessoa-Mahana, Boris Weiss-López & Jorge Ferreira. (2008) Effects of Simple and Angular Chromones on Tumor Cell Respiration. Natural Product Communications 3:4, pages 1934578X0800300.
Crossref
Crossref
Melissa E. Smith, Velasco Cimica, Srinivasa Chinni, Kavitha Challagulla, Sridhar Mani & Ganjam V. Kalpana. (2008) Rhabdoid Tumor Growth is Inhibited by Flavopiridol. Clinical Cancer Research 14:2, pages 523-532.
Crossref
Crossref
Chad D. Knights & Richard G. Pestell. 2008. Molecular Targeting in Oncology. Molecular Targeting in Oncology
3
32
.
Wei Huang, Ming-Zhen Liu, Yan Li, Ying Tan & Guang-Fu Yang. (2007) Design, syntheses, and antitumor activity of novel chromone and aurone derivatives. Bioorganic & Medicinal Chemistry 15:15, pages 5191-5197.
Crossref
Crossref
T Shimanuki, T Hara, T Furuya, T Imamura & K Miyazono. (2006) Modulation of the functional binding sites for TGF-β on the type II receptor leads to suppression of TGF-β signaling. Oncogene 26:23, pages 3311-3320.
Crossref
Crossref
Yu Mi Ahn, Lakshminarayana Vogeti, Chun-Jing Liu, Hari K.R. Santhapuram, Jonathan M. White, Veena Vasandani, Lester A. Mitscher, Gerald H. Lushington, Paul R. Hanson, Douglas R. Powell, Richard H. Himes, Katherine F. Roby, Qizhuang Ye & Gunda I. Georg. (2007) Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. Bioorganic & Medicinal Chemistry 15:2, pages 702-713.
Crossref
Crossref
Kevin J. Moriarty, Holly Koblish, Dana L. Johnson & Robert A. GalemmoJrJr. 2007. Cancer. Cancer
207
291
.
Mahmud Tareq Hassan Khan. 2007. Bioactive Heterocycles III. Bioactive Heterocycles III
33
52
.
Michael B Ujiki, Xian-Zhong Ding, M Reza Salabat, David J Bentrem, Laleh Golkar, Ben Milam, Mark S Talamonti, Richard H BellJrJr, Takeshi Iwamura & Thomas E Adrian. (2006) Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Molecular Cancer 5:1.
Crossref
Crossref
Adrian Senderowicz. 2006. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents
167
186
.
Stéphane Bach, Marc Blondel & Laurent Meijer. 2006. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents
103
119
.
Paul Smith, Emeline Furon & Rachel Errington. 2006. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents
3
27
.
Harish Dureja & Anil Kumar Madan. (2005) Topochemical models for prediction of cyclin-dependent kinase 2 inhibitory activity of indole-2-ones. Journal of Molecular Modeling 11:6, pages 525-531.
Crossref
Crossref
Shun Su, Dayle E. Acquilano, Jeevanandam Arumugasamy, Aaron B. Beeler, Erin L. Eastwood, Joshua R. Giguere, Ping Lan, Xiaoguang Lei, Geanna K. Min, Adam R. Yeager, Ya Zhou, James S. Panek, John K. Snyder, Scott E. Schaus & John A. Porco. (2005) Convergent Synthesis of a Complex Oxime Library Using Chemical Domain Shuffling. Organic Letters 7:13, pages 2751-2754.
Crossref
Crossref
Sharad Verma, Dhanapalan Nagarathnam, Jianxing Shao, Lei Zhang, Jin Zhao, Yamin Wang, Tindy Li, Eric Mull, Istvan Enyedy, Chunguang Wang, Qingming Zhu, Martha Altieri, Jerold Jordan, Thu-Thi-Anh Dang & Sanjeeva Reddy. (2005) Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 15:8, pages 1973-1977.
Crossref
Crossref
Suzy KimHong-Gyun WuJin Hee ShinHye Jin ParkIn Ah KimIl Han Kim. (2005) Enhancement of Radiation Effects by Flavopiridol in Uterine Cervix Cancer Cells. Cancer Research and Treatment 37:3, pages 191.
Crossref
Crossref
W-N P Lee, P Guo, S Lim, S Bassilian, S T Lee, J Boren, M Cascante, V L W Go & L G Boros. (2004) Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. British Journal of Cancer 91:12, pages 2094-2100.
Crossref
Crossref
Marxa L. Figueiredo, Yong Kim, Xiaofeng C. Zhou, Jeffrey N. Myers & David D.T. Wong. (2004) Molecular mechanisms of head and neck cancer. Drug Discovery Today: Disease Mechanisms 1:2, pages 273-281.
Crossref
Crossref
Birgit Jaschke, Stefan Milz, Michael Vogeser, Cornelia Michaelis, Marc Vorpahl, Albert Schömig, Adnan Kastrati & Rainer Wessely. (2004) Local cyclin‐dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug‐ eluting stents to prevent neointima formation following vascular injury. The FASEB Journal 18:11, pages 1285-1287.
Crossref
Crossref
Elizabeth W. Newcomb. (2004) Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anti-Cancer Drugs 15:5, pages 411-419.
Crossref
Crossref
Jim O’Prey, Judith Brown, Janis Fleming & Paul R Harrison. (2003) Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. Biochemical Pharmacology 66:11, pages 2075-2088.
Crossref
Crossref
Antonis Kafanas, Beverly Y. Wang, Tamara Kalir, Li Gan, Carol Bodian, Heidi Fish, D.Stave Kohtz & David E. Burstein. (2003) Immunohistochemical visualization of histone H1 phosphorylation in squamous intraepithelial lesions of the gynecologic tract. Human Pathology 34:2, pages 166-173.
Crossref
Crossref
Steven Grant & John D Roberts. (2003) The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resistance Updates 6:1, pages 15-26.
Crossref
Crossref
Alexander Levitzki. 2003. Handbook of Cell Signaling. Handbook of Cell Signaling
451
461
.
E. RaymondW.W. ten Bokkel HuininkJ. TaïebJ.H. BeijnenS. FaivreJ. WandersM. RavicP. FumoleauJ.P. ArmandJ.H.M. Schellens. (2002) Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer. Journal of Clinical Oncology 20:16, pages 3508-3521.
Crossref
Crossref
Peter L. Toogood. (2001) Cyclin-dependent kinase inhibitors for treating cancer. Medicinal Research Reviews 21:6, pages 487-498.
Crossref
Crossref
Jaume Piulats & Gema Tarrasón. (2001) E2F transcription factors and cancerFactores de transcripción E2F y cáncer. Revista de Oncología 3:5, pages 241-249.
Crossref
Crossref
Michelle Simons-Evelyn, Kim Bailey-Dell, Jeffrey A. Toretsky, Douglas D. Ross, Robert Fenton, Dhan Kalvakolanu & Aaron P. Rapoport. (2001) PBK/TOPK Is a Novel Mitotic Kinase Which Is Upregulated in Burkitt's Lymphoma and Other Highly Proliferative Malignant Cells. Blood Cells, Molecules, and Diseases 27:5, pages 825-829.
Crossref
Crossref
Sheng-Hao Chao & David H. Price. (2001) Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo. Journal of Biological Chemistry 276:34, pages 31793-31799.
Crossref
Crossref
A da Rocha. (2001) Natural products in anticancer therapy. Current Opinion in Pharmacology 1:4, pages 364-369.
Crossref
Crossref
Mari Ikuta, Kenji Kamata, Kazuhiro Fukasawa, Teruki Honma, Takumitsu Machida, Hiroshi Hirai, Ikuko Suzuki-Takahashi, Takashi Hayama & Susumu Nishimura. (2001) Crystallographic Approach to Identification of Cyclin-dependent Kinase 4 (CDK4)-specific Inhibitors by Using CDK4 Mimic CDK2 Protein. Journal of Biological Chemistry 276:29, pages 27548-27554.
Crossref
Crossref
Aaron P. Rapoport, Michelle Simons-Evelyn, Timothy Chen, Rochel Sidell, Shannon Luhowskyj, Karen Rosell, Tom Obrig, David Hicks, Patricia M. Hinkle, Moon Nahm, Richard A. Insel & Camille N. Abboud. (2001) Flavopiridol Induces Apoptosis and Caspase-3 Activation of a Newly Characterized Burkitt's Lymphoma Cell Line Containing Mutant P53 Genes. Blood Cells, Molecules, and Diseases 27:3, pages 610-624.
Crossref
Crossref
A. Kubo & F. J. Kaye. (2001) Searching for Selective Cyclin-Dependent Kinase Inhibitors to Target the Retinoblastoma/p16 Cancer Gene Pathway. JNCI Journal of the National Cancer Institute 93:6, pages 415-417.
Crossref
Crossref
S.David Kimball & Kevin R. Webster. 2001.
139
148
.